Strides Pharma Science Ltd Technical Momentum Shifts Signal Bullish Outlook

Technical Momentum Gains Traction

Strides Pharma Science Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, currently trades at ₹1,220.00, up 1.66% from the previous close of ₹1,200.05. The stock’s intraday range today has been relatively tight, with a low of ₹1,200.00 and a high of ₹1,228.00, nearing its 52-week high of ₹1,231.45. This price action reflects a positive momentum shift, supported by a technical trend upgrade from mildly bullish to bullish.

The daily moving averages have turned decisively bullish, signalling sustained upward price pressure. This is complemented by the weekly and monthly Moving Average Convergence Divergence (MACD) indicators, both of which remain bullish, reinforcing the medium- and long-term momentum strength. The bullish MACD readings suggest that the stock’s upward momentum is likely to continue, as the MACD line remains above its signal line on both weekly and monthly charts.

Mixed Signals from Momentum Oscillators

While the MACD and moving averages paint a positive picture, the Relative Strength Index (RSI) presents a more nuanced view. The weekly RSI currently shows no clear signal, indicating a neutral momentum in the short term. However, the monthly RSI is bearish, suggesting that the stock may be approaching overbought territory or facing some medium-term selling pressure. This divergence between weekly and monthly RSI readings highlights the importance of monitoring momentum oscillators closely for potential reversals or consolidation phases.

Similarly, the Know Sure Thing (KST) oscillator, which is a momentum indicator that smooths price changes over multiple timeframes, is mildly bearish on both weekly and monthly charts. This mild bearishness contrasts with the bullish MACD and moving averages, signalling that while the price trend is upward, momentum strength may be moderating.

Bollinger Bands and On-Balance Volume Confirm Strength

Bollinger Bands, which measure price volatility and potential overbought or oversold conditions, are bullish on both weekly and monthly timeframes. This suggests that the stock is trading near the upper band, consistent with a strong upward trend and increased volatility. The On-Balance Volume (OBV) indicator also supports this view, showing bullish readings on weekly and monthly charts. Rising OBV indicates that volume is confirming the price advances, a positive sign for sustained momentum.

Dow Theory and Trend Assessment

According to Dow Theory, the weekly trend is mildly bullish, while the monthly trend is mildly bearish. This mixed assessment reflects the stock’s current position at a technical inflection point, where short-term strength is evident but longer-term caution remains warranted. Investors should watch for confirmation of trend continuation or reversal in the coming weeks.

Strong Relative Performance Against Sensex

Strides Pharma Science Ltd has outperformed the broader market significantly over multiple time horizons. Over the past week, the stock returned 2.86%, compared to a Sensex decline of 0.65%. The one-month return stands at an impressive 29.02%, while the Sensex fell 3.81% in the same period. Year-to-date, Strides Pharma has gained 35.20%, vastly outperforming the Sensex’s negative 12.82% return. Over one year, the stock’s return of 39.25% contrasts sharply with the Sensex’s -10.50%.

Longer-term performance is even more striking, with a three-year return of 449.18% versus the Sensex’s 9.91%, and a five-year return of 337.98% compared to the Sensex’s 25.89%. Even over a decade, Strides Pharma’s 181.59% return surpasses the Sensex’s 159.78%, underscoring the company’s consistent outperformance and resilience in the Pharmaceuticals & Biotechnology sector.

Mojo Score and Rating Revision

MarketsMOJO currently assigns Strides Pharma Science Ltd a Mojo Score of 64.0, reflecting a Hold rating. This represents a downgrade from a previous Buy rating as of 15 Sep 2026. The downgrade aligns with the mixed technical signals observed, particularly the bearish monthly RSI and KST indicators, which temper the otherwise bullish momentum. The small-cap status of the company also suggests a degree of volatility and risk that investors should consider.

Implications for Investors

The technical upgrade to a bullish trend, supported by strong MACD and moving averages, indicates that Strides Pharma Science Ltd is currently in a favourable price momentum phase. However, the cautionary signals from monthly RSI and KST oscillators suggest that investors should remain vigilant for potential pullbacks or consolidation. The stock’s strong relative performance against the Sensex over multiple timeframes adds confidence to its growth prospects, but the recent rating downgrade to Hold advises a measured approach.

Investors with a medium- to long-term horizon may find value in the stock’s consistent outperformance and fundamental strength, while short-term traders should monitor momentum oscillators closely for signs of exhaustion or reversal.

Conclusion: A Bullish Outlook with Cautionary Notes

Strides Pharma Science Ltd’s recent technical parameter changes signal a strengthening bullish momentum, supported by key indicators such as MACD, moving averages, Bollinger Bands, and OBV. The stock’s price action near its 52-week high and strong relative returns against the Sensex reinforce its positive trajectory. However, the bearish monthly RSI and KST readings, alongside a Hold rating from MarketsMOJO, suggest that investors should approach with caution and monitor momentum indicators closely.

Overall, Strides Pharma remains a compelling small-cap stock within the Pharmaceuticals & Biotechnology sector, offering a blend of growth potential and technical strength. Investors are advised to balance optimism with prudence, considering both the bullish signals and the subtle warning signs embedded in the technical data.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today